NOVATO, Calif. (AP) — BioMarin Pharmaceutical Inc. said Tuesday it does not expect manufacturing issues for partner Genzyme Corp. to lead to reduced supplies of its Aldurazyme enzyme replacement therapy. Late Monday, Genzyme was told to correct problems at a manufacturing plant in Allston, Mass., in order to get a new drug approved for sale. BioMarin said sales of Aldurazyme won’t be affected because there were no product recalls, and the companies have enough Aldurazyme available to meet demand. BioMarin said it is also working to get a third supplier qualified to produce the drug. Cambridge, Mass.-based Genzyme sells Aldurazyme, and BioMarin gets a portion of the revenue because it developed the drug. Aldurazyme is used to treat the potentially fatal disease MPS I.
